Y-Intercept (HK)’s ADMA Biologics ADMA Stock Holding History

Y-Intercept (HK)’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.8M	Sell	573,581 -501,841	-47%	-$4.57M	0.1%	289
2026 Q1	$9.69M	Buy	1,075,422 +1,008,548	+1,508%	+$15.9M	0.18%	115
2025 Q4	$1.22M	Sell	66,874 -38,409	-36%	-$647K	0.03%	886
2025 Q3	$1.54M	Buy	105,283 +30,392	+41%	+$521K	0.04%	764
2025 Q2	$1.36M	Buy	74,891 +38,809	+108%	+$791K	0.03%	786
2025 Q1	$716K	Buy	36,082 +6,333	+21%	+$110K	0.05%	544
2024 Q4	$510K	Buy	+29,749	New	+$560K	0.03%	714
2024 Q3	–	Sell	-34,055	Closed	-$381K	–	1249
2024 Q2	$381K	Buy	+34,055	New	+$286K	0.02%	935
2023 Q3	–	Sell	-19,204	Closed	-$70.9K	–	1008
2023 Q2	$70.9K	Buy	+19,204	New	+$71.2K	0.01%	1164
2022 Q2	–	Sell	-48,328	Closed	-$88K	–	831
2022 Q1	$88K	Buy	+48,328	New	+$75.4K	0.02%	680
2021 Q3	–	Sell	-16,656	Closed	-$27K	–	620
2021 Q2	$27K	Buy	+16,656	New	+$29.3K	0.01%	576

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Y-Intercept (HK)'s ADMA Position: Q2 2026 in Review

Y-Intercept (HK) reduced its ADMA Biologics (ADMA) stake by 47% in Q2 2026, selling an estimated $4.57M and leaving 573,581 shares worth $4.8M. The position accounts for 0.1% of the portfolio, ranked #289.

Y-Intercept (HK) first reported a position in ADMA in Q2 2021 and has held it in 11 quarters since. The position peaked at $9.69M in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Y-Intercept (HK) held 573,581 shares of ADMA Biologics worth $4.8M as of Q2 2026.
Y-Intercept (HK) sold 501,841 ADMA Biologics shares in Q2 2026, an estimated $4.57M.
ADMA Biologics made up 0.1% of Y-Intercept (HK)'s portfolio in Q2 2026, its #289 holding.
Y-Intercept (HK) first reported a position in ADMA Biologics in Q2 2021 and has held it in 11 quarters since.
Y-Intercept (HK)'s ADMA Biologics position peaked at $9.69M in Q1 2026.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.